This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pichiorri, F. Articles by Croce, C. M. Search for Related Content PubMed PubMed Citation Articles by Pichiorri, F. Articles by Croce, C. M.

Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35

Authors' Affiliations: ¹ Ohio State University Comprehensive Cancer Center, Columbus, Ohio; ² Department of Biopathology and Image Diagnostics, University "Tor Vergata" of Rome, Rome, Italy; ³ Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy; and ⁴ Department of Experimental and Clinical Pharmacology, University of Catania, Catania, Italy

Requests for reprints: Flavia Pichiorri, Ohio State University Comprehensive Cancer Center, Wiseman Hall, Room 441, 410 West 12th Avenue, Columbus, OH 43210. Phone: 614-292-4354; E-mail: pichiorri.1{at}osu.edu.

Purpose: Expression of the FHIT protein is lost or reduced in most solid tumors and a significant fraction of hematopoietic malignancies. Adenovirus 5 (Ad5) virus or adeno-associated viral vectors have been used to study the tumor suppressor function of FHIT in solid tumors, but these tools have not been effective in leukemias. We have generated a chimeric FHIT-containing adenovirus composed of Ad5 and the group B adenovirus called F35 with which we have been able to efficiently infect hematopoietic cells.

Experimental Design: Infection efficiency of Ad5/F35-FHIT and Ad5/F35-GFP viruses was tested in leukemia cell lines that lacked FHIT expression, and biological effects of successful infection were assessed. An acute myelogenous leukemia, a chronic myelogenous leukemia, and four acute lymphoblastic leukemia human cell lines were examined as well as two EBV-transformed B lymphoblastoid cell lines that expressed endogenous FHIT.

Results: Two of four acute lymphoblastic leukemia cell lines, Jurkat and MV4;11, which were efficiently infected with Ad5/F35-FHIT, underwent growth suppression and massive induction of apoptosis without apparent activation of caspase-8 or caspase-2 and late activation of caspase-3. Treatment of infected cells with caspase-9 and caspase-3 inhibitors partially blocked FHIT-induced apoptosis. The two remaining infected acute lymphoblastic leukemia cell lines, Molt-3 and RS4;11, were apparently unaffected. Restoration of FHIT expression in the chronic myelogenous leukemia K562 cell line and the acute myelogenous leukemia KG1a cell line also induced apoptosis but at later time points than seen in the acute lymphoblastic leukemia Jurkat and MV4;11 cell lines. I.v. injection of Ad5/F35-FHIT-infected Jurkat cells resulted in abrogation of tumorigenicity in the NOD/SCID xenogeneic engraftment model.

Conclusion: FHIT restoration in some FHIT-deficient leukemia cells induces both antiproliferative and proapoptotic effects involving the intrinsic caspase apoptotic pathway.

This article has been cited by other articles:

				S. V. Sharma and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes & Dev., December 15, 2007; 21(24): 3214 - 3231. [Abstract] [Full Text] [PDF]

				O. Kujan, R. Oliver, L. Roz, G. Sozzi, N. Ribeiro, R. Woodwards, N. Thakker, and P. Sloan Fragile Histidine Triad Expression in Oral Squamous Cell Carcinoma and Precursor Lesions. Clin. Cancer Res., November 15, 2006; 12(22): 6723 - 6729. [Abstract] [Full Text] [PDF]